MX2020005332A - Polimorfos y formas solidas de un compuesto de pirimidinilamino-pirazol y metodos de produccion. - Google Patents
Polimorfos y formas solidas de un compuesto de pirimidinilamino-pirazol y metodos de produccion.Info
- Publication number
- MX2020005332A MX2020005332A MX2020005332A MX2020005332A MX2020005332A MX 2020005332 A MX2020005332 A MX 2020005332A MX 2020005332 A MX2020005332 A MX 2020005332A MX 2020005332 A MX2020005332 A MX 2020005332A MX 2020005332 A MX2020005332 A MX 2020005332A
- Authority
- MX
- Mexico
- Prior art keywords
- pyrimidinylamino
- polymorphs
- production
- methods
- solid forms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente descripción hace referencia a formas amorfas y polimórficas cristalinas de 2-metil-2-(3- metil-4-(4-(metilamino)- 5-(trifluorometil)pirimidin-2-ilamino)-1H-pirazol-1-il)propanonit rilo o solvatos, tautómeros y cocristales o sales farmacéuticamente aceptables de este, así como a procesos para su elaboración.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762589276P | 2017-11-21 | 2017-11-21 | |
| PCT/US2018/062102 WO2019104086A1 (en) | 2017-11-21 | 2018-11-20 | Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020005332A true MX2020005332A (es) | 2021-01-08 |
Family
ID=66631734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020005332A MX2020005332A (es) | 2017-11-21 | 2018-11-20 | Polimorfos y formas solidas de un compuesto de pirimidinilamino-pirazol y metodos de produccion. |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US10370361B2 (es) |
| EP (1) | EP3717473B1 (es) |
| JP (1) | JP7303821B2 (es) |
| KR (1) | KR20200089713A (es) |
| CN (1) | CN111819174A (es) |
| AR (1) | AR113893A1 (es) |
| AU (1) | AU2018372180B2 (es) |
| BR (1) | BR112020010215A2 (es) |
| CA (1) | CA3083022A1 (es) |
| CL (1) | CL2020001346A1 (es) |
| CO (1) | CO2020006206A2 (es) |
| CR (1) | CR20200216A (es) |
| EA (1) | EA202091279A1 (es) |
| ES (1) | ES2975319T3 (es) |
| IL (1) | IL274824A (es) |
| JO (1) | JOP20200128A1 (es) |
| MA (1) | MA51222A (es) |
| MX (1) | MX2020005332A (es) |
| PE (1) | PE20210157A1 (es) |
| SG (1) | SG11202004733WA (es) |
| TW (1) | TWI823878B (es) |
| UA (1) | UA126414C2 (es) |
| WO (1) | WO2019104086A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020005332A (es) * | 2017-11-21 | 2021-01-08 | Denali Therapeutics Inc | Polimorfos y formas solidas de un compuesto de pirimidinilamino-pirazol y metodos de produccion. |
| WO2019126383A1 (en) | 2017-12-20 | 2019-06-27 | Denali Therapeutics Inc. | Process for the preparation of pyrimidinyl-4-aminopyrazole compounds |
| WO2023174946A1 (en) | 2022-03-15 | 2023-09-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Early and non-invasive method for assessing a subject's risk of having parkinson's disease |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2574168T3 (en) * | 2010-05-21 | 2016-05-09 | Incyte Holdings Corp | Topical formulation to a jak inhibitor |
| AU2011260323A1 (en) | 2010-06-04 | 2012-11-15 | F. Hoffmann-La Roche Ag | Aminopyrimidine derivatives as LRRK2 modulators |
| GB201015949D0 (en) | 2010-09-22 | 2010-11-03 | Medical Res Council Technology | Compounds |
| LT3124483T (lt) | 2010-11-10 | 2019-09-25 | Genentech, Inc. | Pirazolo aminopirimidino dariniai, kaip lrrk2 moduliatoriai |
| RU2634716C2 (ru) | 2011-11-29 | 2017-11-03 | Дженентек, Инк. | Производные аминопиридина в качестве модуляторов богатой лейцином повторной киназы 2 (lrrk2) |
| AR089182A1 (es) | 2011-11-29 | 2014-08-06 | Hoffmann La Roche | Derivados de aminopirimidina como moduladores de lrrk2 |
| KR102012057B1 (ko) | 2011-11-29 | 2019-08-19 | 제넨테크, 인크. | Lrrk2 조절제로서 아미노피리미딘 유도체 |
| CN106243090A (zh) | 2011-11-29 | 2016-12-21 | 霍夫曼-拉罗奇有限公司 | 作为用于治疗帕金森病的激酶lrrk2调节剂的2‑(苯基或吡啶‑3‑基)氨基嘧啶衍生物 |
| RU2637947C2 (ru) | 2012-05-03 | 2017-12-08 | Дженентек, Инк. | Производные пиразоламинопиримидина в качестве модуляторов обогащенной лейциновыми повторами киназы 2 |
| CN106279202A (zh) | 2012-05-03 | 2017-01-04 | 霍夫曼-拉罗奇有限公司 | 作为lrrk2调节剂用于治疗帕金森病的吡唑氨基嘧啶衍生物 |
| CU24605B1 (es) | 2016-06-16 | 2022-06-06 | Denali Therapeutics Inc | Pirimidin-2-il amino-1h-pirazoles útiles como inhibidores de lrrk2 |
| MX2020005332A (es) * | 2017-11-21 | 2021-01-08 | Denali Therapeutics Inc | Polimorfos y formas solidas de un compuesto de pirimidinilamino-pirazol y metodos de produccion. |
-
2018
- 2018-11-20 MX MX2020005332A patent/MX2020005332A/es unknown
- 2018-11-20 WO PCT/US2018/062102 patent/WO2019104086A1/en active Application Filing
- 2018-11-20 EA EA202091279A patent/EA202091279A1/ru unknown
- 2018-11-20 EP EP18881859.5A patent/EP3717473B1/en active Active
- 2018-11-20 MA MA051222A patent/MA51222A/fr unknown
- 2018-11-20 AR ARP180103389A patent/AR113893A1/es unknown
- 2018-11-20 JP JP2020545076A patent/JP7303821B2/ja active Active
- 2018-11-20 AU AU2018372180A patent/AU2018372180B2/en active Active
- 2018-11-20 TW TW107141257A patent/TWI823878B/zh active
- 2018-11-20 CN CN201880081321.5A patent/CN111819174A/zh active Pending
- 2018-11-20 ES ES18881859T patent/ES2975319T3/es active Active
- 2018-11-20 UA UAA202003681A patent/UA126414C2/uk unknown
- 2018-11-20 CR CR20200216A patent/CR20200216A/es unknown
- 2018-11-20 KR KR1020207017598A patent/KR20200089713A/ko not_active Application Discontinuation
- 2018-11-20 SG SG11202004733WA patent/SG11202004733WA/en unknown
- 2018-11-20 US US16/197,037 patent/US10370361B2/en active Active
- 2018-11-20 JO JOP/2020/0128A patent/JOP20200128A1/ar unknown
- 2018-11-20 PE PE2020000558A patent/PE20210157A1/es unknown
- 2018-11-20 BR BR112020010215-6A patent/BR112020010215A2/pt unknown
- 2018-11-20 CA CA3083022A patent/CA3083022A1/en active Pending
-
2019
- 2019-06-20 US US16/447,713 patent/US10851088B2/en active Active
-
2020
- 2020-05-20 IL IL274824A patent/IL274824A/en unknown
- 2020-05-21 CO CONC2020/0006206A patent/CO2020006206A2/es unknown
- 2020-05-21 CL CL2020001346A patent/CL2020001346A1/es unknown
- 2020-11-27 US US17/105,870 patent/US11427571B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| UA126414C2 (uk) | 2022-09-28 |
| PE20210157A1 (es) | 2021-01-26 |
| JP2021504450A (ja) | 2021-02-15 |
| US20190315723A1 (en) | 2019-10-17 |
| AU2018372180B2 (en) | 2023-08-17 |
| US10370361B2 (en) | 2019-08-06 |
| US20210087176A1 (en) | 2021-03-25 |
| CR20200216A (es) | 2021-03-19 |
| CN111819174A (zh) | 2020-10-23 |
| CL2020001346A1 (es) | 2020-11-20 |
| ES2975319T3 (es) | 2024-07-04 |
| KR20200089713A (ko) | 2020-07-27 |
| SG11202004733WA (en) | 2020-06-29 |
| JP7303821B2 (ja) | 2023-07-05 |
| EA202091279A1 (ru) | 2020-08-19 |
| US11427571B2 (en) | 2022-08-30 |
| US20190194170A1 (en) | 2019-06-27 |
| CO2020006206A2 (es) | 2020-08-10 |
| CA3083022A1 (en) | 2019-05-31 |
| EP3717473A4 (en) | 2021-07-07 |
| MA51222A (fr) | 2020-10-07 |
| TWI823878B (zh) | 2023-12-01 |
| EP3717473B1 (en) | 2024-01-10 |
| IL274824A (en) | 2020-07-30 |
| JOP20200128A1 (ar) | 2020-05-21 |
| AU2018372180A1 (en) | 2020-06-18 |
| BR112020010215A2 (pt) | 2020-11-03 |
| AR113893A1 (es) | 2020-06-24 |
| TW201925190A (zh) | 2019-07-01 |
| EP3717473A1 (en) | 2020-10-07 |
| WO2019104086A1 (en) | 2019-05-31 |
| US10851088B2 (en) | 2020-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018550120A1 (en) | Steroid derivative fxr agonist | |
| MX2021009764A (es) | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona sustituidos y usos de los mismos. | |
| MX2020002060A (es) | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos. | |
| IL279101A (en) | Salts of spiafatrin are accepted in pharmacies | |
| MX2021009763A (es) | Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos. | |
| MX2016009403A (es) | Compuestos heterociclicos. | |
| MD3882250T2 (ro) | Tetrahidropiranil-amino-pirolopirimidinona pentru utilizare într-un procedeu de tratament al unei tulburări mediate de BTK | |
| MX2019005244A (es) | Acidos propionicos 3-sustituidos como inhibidores de la integrina alfa v. | |
| WO2014192030A3 (en) | An improved process for preparation of dabigatran etexilate and pharmaceutically acceptable acid addition salts thereof | |
| EA201791304A1 (ru) | Производные изохинолина для лечения вич | |
| MX2021008002A (es) | Sales nuevas y forma polimorfica del acido bempedoico. | |
| MX2020005332A (es) | Polimorfos y formas solidas de un compuesto de pirimidinilamino-pirazol y metodos de produccion. | |
| PH12016501903B1 (en) | Novel fused imidazobenzothiazole compounds | |
| PH12016502246A1 (en) | Carboxamide derivatives | |
| MX2016014946A (es) | Derivados de carboxamida. | |
| WO2016023028A3 (en) | G protein-coupled receptor kinase 2 inhibitors and methods for use of the same | |
| HK1254731A1 (zh) | 用於醫學應用的3-(1，2，4-三唑並[4，3-a]吡啶-3-基乙炔基)-4-甲基-n-(4-((4-甲基哌嗪-1-基)甲基)-3-三氟甲基苯基)苯甲酰胺的新型結晶鹽形式 | |
| PH12017501532A1 (en) | Crystalline forms of a pyrrolopyridine compound | |
| PH12017500323B1 (en) | P38 map kinase inhibiting indanyl urea compounds | |
| MX2018015990A (es) | Compuestos terapeuticos. | |
| NZ748942A (en) | Pyrazolylaminobenzimidazole derivatives as jak inhibitors | |
| ZA202008062B (en) | Pharmaceutically acceptable salts of sepiapterin | |
| PH12020500385A1 (en) | A process for preparation of triaminopyrimidine compound and intermediates thereof | |
| PH12016502247A1 (en) | Carboxamide derivatives | |
| TH163399B (th) | การสังเคราะห์ 3-(5อะมิโน-2-เมธิล-4-ออกโซควินาโซลิน-3(4h)-อิล)ไพเพอริดีน-2,6-ไดโอน |